Skip to main content

Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial

September 23, 2021

July 2021- There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL in Malawi. This prospective, … Continued

Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis

September 23, 2021

July 2021- Cost-effectiveness data for cancer treatment are needed from sub-Saharan Africa, where diffuse large B-cell lymphoma (DLBCL) is a common, curable cancer. In high-income countries, the standard of care for DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemoimmunotherapy. Rituximab is often not available in sub-Saharan Africa due to perceived unaffordability, and treatment … Continued

Feasibility of upfront mobile money transfers for transportation reimbursement to promote retention among patients receiving lymphoma treatment in Malawi

September 23, 2021

May 2021-Cancer outcomes in sub-Saharan Africa (SSA) remain suboptimal, in part due to poor patient retention. Many patients travel long distances to receive care, and transportation costs are often prohibitively expensive. These are well-known and established causes of delayed treatment and care abandonment in Malawi and across SSA. We sent visit reminder texts and offered … Continued

Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains

September 23, 2021

August 2021- Patient-reported outcomes (PROs) that assess health-related quality of life (HRQoL) are increasingly important components of cancer care and research that are infrequently used in sub-Saharan Africa (SSA). We administered the Chichewa Pediatric Patient-Reported Outcome Measurement Information System Pediatric (PROMIS)-25 at diagnosis, active treatment, and follow-up among pediatric lymphoma patients in Lilongwe, Malawi. Mean … Continued

Epidemiology of haematological malignancies in people living with HIV

September 23, 2021

August 2020- SERIES: People living with HIV or AIDS are at increased risk of Hodgkin and non-Hodgkin lymphoma compared with HIV-negative individuals. Data on the risk of multiple myeloma or leukaemia are inconsistent and of low quality but the risk does not seem to be increased. Specific haematological malignancies occur in different contexts of age, … Continued

Improving outcomes for non-Hodgkin lymphoma in Sub-Saharan Africa: where to start?

September 23, 2021

March 2020- COMMENTARY: As governments in sub-Saharan Africa (SSA) expand access to effective antiretroviral therapy (ART) for HIV-infected patients, cancer is becoming an increasingly important cause of preventable death in the region. According to the Global Burden of Disease study, cancer is now the second leading cause of death worldwide, and, despite decreases in cancer … Continued

Modified EPOCH for High-Risk Non-Hodgkin Lymphoma in Sub-Saharan Africa

January 10, 2020

January 2020 – Aggressive NHL is among the most common cancers in SSA where CHOP is the standard treatment and outcomes are poor. We treated patients with a modified EPOCH regimen with moderate outcomes. Results indicate that this regimen was feasible and effective in a small cohort and suggest EPOCH with setting-appropriate modifications may be … Continued

Facilitators and Barriers to Traditional Medicine Use Among Malawian Cancer Patients

October 10, 2019

October 2019 – Increasing access to conventional cancer treatment in low-income countries is an important public health initiative to address the global burden of cancer. Our findings indicate that cancer patients in our cohort rely on a pragmatic and experience-based treatment selection process and provide insights to the various factors that influence T&CM use among cancer … Continued